Aims and Scope of Drug Target Insights
Drug Target Insights (DTI) is an international, indexed, peer-reviewed, open access, online only journal, published once a year. It covers current developments in all areas of the field of clinical therapeutics and focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes. The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life. The journal welcomes unsolicited article proposals. All articles are listed on PubMed and are freely available via PubMed Central. Less
Key Metrics
CiteScore 

4.3
SJR 

Q2Clinical Biochemistry

SNIP 

0.65
Recommended pre-submission checks
Powered by 

Drug Target Insights Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | ABOUTSCIENCE SRL |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 1500 |
| Publication Time | 8 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2006 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Publication Time | 8 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Drug Target Insights ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Drug Target Insights
Optimizing ChEMBL-derived QSAR models for natural flavonoid screening: chemotype-specific predictive reliability in \u03b1-glucosidase-inhibition
- 5 Oct 2026
- Drug Target Insights
Erratum in: In vitro and molecular docking evaluation of apigenin-7-O-glucuronide from Psorospermum febrifugum as anti-inflammatory and predicted antiplasmodial compound
- 7 Sep 2026
- Drug Target Insights
In vitro and molecular docking evaluation of apigenin-7-O-glucuronide from Psorospermum febrifugum as anti-inflammatory and predicted antiplasmodial compound
- 4 Aug 2026
- Drug Target Insights
Withania somnifera root extract reduces susceptibility of the model worm Caenorhabditis elegans to different types of stressors
- 20 Jul 2026
- Drug Target Insights
Comparative effects of Helmar-1 and Helmar-2 polyphenol extracts on mitochondrial bioenergetics, antioxidant defense, and lipid peroxidation in CCl₄-induced toxic hepatitis in rats.
- 13 Jul 2026
- Drug target insights
Molecular docking and dynamics analysis of selected phytocompounds against multi-targeted hepatocellular carcinoma.
- 23 Apr 2026
- Drug target insights
Optimizing ChEMBL-derived QSAR models for natural flavonoid screening: chemotype-specific predictive reliability in \u03b1-glucosidase-inhibition
- 5 Oct 2026
- Drug Target Insights
Erratum in: In vitro and molecular docking evaluation of apigenin-7-O-glucuronide from Psorospermum febrifugum as anti-inflammatory and predicted antiplasmodial compound
- 7 Sep 2026
- Drug Target Insights
In vitro and molecular docking evaluation of apigenin-7-O-glucuronide from Psorospermum febrifugum as anti-inflammatory and predicted antiplasmodial compound
- 4 Aug 2026
- Drug Target Insights
Withania somnifera root extract reduces susceptibility of the model worm Caenorhabditis elegans to different types of stressors
- 20 Jul 2026
- Drug Target Insights
Comparative effects of Helmar-1 and Helmar-2 polyphenol extracts on mitochondrial bioenergetics, antioxidant defense, and lipid peroxidation in CCl₄-induced toxic hepatitis in rats.
- 13 Jul 2026
- Drug target insights
Molecular docking and dynamics analysis of selected phytocompounds against multi-targeted hepatocellular carcinoma.
- 23 Apr 2026
- Drug target insights